Category Archives: Clinical Cardiology

SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21) taking place online from May 15, 2021 - May 17, 2021. Included among these presentations will be a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction, in a Late Breaking Clinical Trial session. Late Breaking Clinical Trial Session Title: 410-16 Impact of Ejection Fraction on the Therapeutic Effect of Omecamtiv Mecarbil In Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis From GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) Presenter: John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF Date: May 17, 2021 Session Title: Late-Breaking Clinical Trials IV Session Time: 8:00 9:15 AM ET Presentation Time: 9:00 9:10 AM ET Poster Presentations The following posters will be available on demand for registered attendees beginning on May 15, 2021 at 8:00 AM ET. Continue reading →

Written by Julia Ries on May 7, 2021 Fact checked by Dana K. Continue reading →

NEW YORK--(BUSINESS WIRE)--Heartbeat Health, a healthcare company working to deliver the most effective, efficient, and engaging heart care, announced today that it has raised $20 million in Series B funding, led by Echo Health Ventures, with participation from DaVita Venture Group and existing investors, .406 Ventures, Optum Ventures, Kindred Ventures, Lerer Hippeau, Designer Fund and Max Ventures. Heartbeat Health was founded with a mission to fundamentally reshape cardiovascular care to better address heart disease, the costliest and deadliest disease globally. Heartbeat delivers virtual-first cardiovascular disease prevention and management with a focus on improved clinical experience, health outcomes, and reduced costs Continue reading →

Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast. For the week ending May 7, 2021, John Mandrola, MD comments on the following news and features stories. Continue reading →

Treatment with canagliflozin may not provide a significant reduction in myocardial infarction (MI) risk among patients with type 2 diabetes (T2D) and comorbid chronic kidney disease (CKD) or among patients with diabetes who have a history of or have a high risk for cardiovascular disease (CVD), a study in Cardiovascular Research suggested. The study was a pooled analysis of 14,543 patients from the CANVAS program and CREDENCE trial Continue reading →

Nanomedicine-Market Latest research on Global Nanomedicine Market report covers forecast and analysis on a worldwide, regional and country level. The study provides historical information of 2016-2021 together with a forecast from 2021 to 2026 supported by both volume and revenue (USD million) Continue reading →

(BPT) - As the world looks with hope to the light at the end of the COVID-19 tunnel, there lies another ongoing health crisis that, according to the American Heart Association (AHA), kills more Americans than anything else: heart disease. In the last year, heart disease claimed more than 690,000 lives in the U.S., which is staggeringly more than the reported 345,000 lives lost to COVID-19, according to data from the Centers for Disease Control and Prevention. With the prevalence of this disease and the large amount of clinical data surrounding the management of CV risk factors, one would assume that the approaches used to reduce the risk of a CV event, such as a heart attack or stroke, would be standard practice Continue reading →

Patients with cardiovascular disease who are under added strain due to sociodemographic factors, such as financial instability and food insecurity, are less likely to take steps to protect themselves from COVID-19 and less able to avoid situations, like crowded work or living spaces, that carry the risk of exposure to SARS-CoV-2. The results, from a survey of US adults during the pandemics first wave, are set to be presented at the virtual American College of Cardiology (ACC) 2021 Scientific Session later this month and are now published in Circulation: Cardiovascular Quality and Outcomes. Prior studies have shown that social determinants of health (SDOH) have an additive effect on cardiovascular health, a risk that persists even when accounting for more-traditional markers like comorbidities and smoking Continue reading →

For patients with atrial fibrillation (AF), current guidelines on diagnosis and management of AF by the European Society for Cardiology (ESC) highlight the importance of identifying and managing risk factors that may exacerbate adverse events. In a commentary published by IJC Heart & Vasculature, authors Dominik Linz, MD, PhD, Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Institute, and Dobromir Dobrev, MD, Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, discussed the implications that management of sleep-disordered breathing (SBD), which is among the listed risk factors, can have on outcomes in patients with AF. Continue reading →

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Workers at Garfield Medical Center in suburban Los Angeles were on edge as the pandemic ramped up in March and April Continue reading →